A deluge of weight‑loss drugs is set to transform the global fight against obesity as India prepares to unleash low‑cost ...

Rhythm Pharmaceuticals stock ultimately closed down Friday, though the FDA signed off on its drug, Imcivree, for a genetic ...

At its peak, Imcivree’s sales in hypothalamic obesity could reach over $2 billion worldwide, according to analysts at Stifel.

A Phase III trial of Rhythm Pharmaceuticals’ Imcivree (setmelanotide) failed to meet its primary endpoints in four rare, ...

By Sneha S K and Sahil Pandey March 20 (Reuters) - The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’ therapy for a rare form of obesity caused by brain damage, making ...

As Eli Lilly begins to take the next generation of obesity drugs to regulators this year, a lower-profile collaboration ...

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

Imcivree’s clearance in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

The Food and Drug Administration approved a higher-dose version of a popular class of obesity drugs on Thursday, the latest expansion in a rapidly growing market for weight-loss treatments. The newly ...

Obesity increases the body's need for insulin, forcing cells in the pancreas known as beta cells to ramp up insulin ...

Obesity is a chronic disease that can significantly affect an individual’s overall health. In this Care Cues, experts discuss ...

UK children are getting taller. The reason why reveals a troubling story about obesity, inequality and poverty.